| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Joseph M Schrader, Craig M Irving, J Christopher Octeau, Joseph A Christian, Timothy J Aballo, Dean J Kareemo, Joseph Conti, Jodi L Camberg, J Robert Lane, Jonathan A Javitch, Abraham Kovoo. The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface. The Journal of biological chemistry. vol 294. issue 14. 2019-10-16. PMID:30670597. |
thus, our observations could provide a cellular explanation for some of the distinct therapeutic characteristics of clozapine in schizophrenia. |
2019-10-16 |
2023-08-13 |
Not clear |
| Dan J Siskind, Michael Lee, Arul Ravindran, Qichen Zhang, Evelyn Ma, Balaji Motamarri, Steve Kisel. Augmentation strategies for clozapine refractory schizophrenia: A systematic review and meta-analysis. The Australian and New Zealand journal of psychiatry. vol 52. issue 8. 2019-10-14. PMID:29732913. |
augmentation strategies for clozapine refractory schizophrenia: a systematic review and meta-analysis. |
2019-10-14 |
2023-08-13 |
Not clear |
| C Okhuijsen-Pfeifer, E A H Huijsman, A Hasan, I E C Sommer, S Leucht, R S Kahn, J J Luyk. Clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. Acta psychiatrica Scandinavica. vol 138. issue 4. 2019-10-11. PMID:30218445. |
clozapine as a first- or second-line treatment in schizophrenia: a systematic review and meta-analysis. |
2019-10-11 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, Yu-Jhen Huang, Po-Wei Chen, Hui-Ting Yang, Hsien-Yuan Lan. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological psychiatry. vol 84. issue 6. 2019-10-08. PMID:29397899. |
sodium benzoate, a d-amino acid oxidase inhibitor, added to clozapine for the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. |
2019-10-08 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, Yu-Jhen Huang, Po-Wei Chen, Hui-Ting Yang, Hsien-Yuan Lan. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological psychiatry. vol 84. issue 6. 2019-10-08. PMID:29397899. |
clozapine is the last-line antipsychotic agent for refractory schizophrenia. |
2019-10-08 |
2023-08-13 |
Not clear |
| Chieh-Hsin Lin, Ching-Hua Lin, Yue-Cune Chang, Yu-Jhen Huang, Po-Wei Chen, Hui-Ting Yang, Hsien-Yuan Lan. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial. Biological psychiatry. vol 84. issue 6. 2019-10-08. PMID:29397899. |
this study aimed to examine the efficacy and safety of a d-amino acid oxidase inhibitor, sodium benzoate, for schizophrenia patients who had poor response to clozapine. |
2019-10-08 |
2023-08-13 |
Not clear |
| Laura M Steinauer, Jonathan G Leung, Betsy Walters Burkey, Ian R McGrane, Victoria Letts, Jessica L Goren, Dawn M Hoeft, Sandra Mullen, Megan Maroney, Kathryn M Schak, Jennifer L Vande Voor. A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization. Journal of child and adolescent psychopharmacology. vol 28. issue 9. 2019-10-04. PMID:30358422. |
clozapine is the drug of choice for treatment-resistant schizophrenia. |
2019-10-04 |
2023-08-13 |
Not clear |
| Andrew T Olagunju, Scott R Clark, Bernhard T Baun. Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis. CNS drugs. vol 32. issue 11. 2019-10-02. PMID:30155842. |
clozapine and psychosocial function in schizophrenia: a systematic review and meta-analysis. |
2019-10-02 |
2023-08-13 |
Not clear |
| Andrew T Olagunju, Scott R Clark, Bernhard T Baun. Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis. CNS drugs. vol 32. issue 11. 2019-10-02. PMID:30155842. |
clozapine has unique efficacy for symptoms in treatment-resistant schizophrenia; however, symptomatic remission is not necessary nor sufficient for functional improvement. |
2019-10-02 |
2023-08-13 |
Not clear |
| Trevor C Chopko, Craig W Lindsle. Classics in Chemical Neuroscience: Risperidone. ACS chemical neuroscience. vol 9. issue 7. 2019-09-30. PMID:29695153. |
risperidone, sold under the trade name risperdal, was the second atypical antipsychotic developed following clozapine but quickly became a first-line treatment for acute and chronic schizophrenia because of its preferential side effect profile. |
2019-09-30 |
2023-08-13 |
Not clear |
| Amir Krivoy, Moshe Hoshen, Tsvi Fischel, Michal Taler, Aviv Segev, Abraham Weizma. [THERE IS ROOM FOR IMPROVEMENT: THE RATE OF CLOZAPINE USE AMONG PATIENTS WITH SCHIZOPHRENIA IN ISRAEL]. Harefuah. vol 158. issue 7. 2019-09-26. PMID:31339244. |
[there is room for improvement: the rate of clozapine use among patients with schizophrenia in israel]. |
2019-09-26 |
2023-08-13 |
Not clear |
| Gang Wang, Wei Zheng, Xian-Bin Li, Shi-Bin Wang, Dong-Bin Cai, Xin-Hu Yang, Gabor S Ungvari, Yu-Tao Xiang, Christoph U Correl. ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials. Journal of psychiatric research. vol 105. 2019-09-10. PMID:30144667. |
ect augmentation of clozapine for clozapine-resistant schizophrenia: a meta-analysis of randomized controlled trials. |
2019-09-10 |
2023-08-13 |
Not clear |
| Noppawan Tunsirimas, Pornjira Pariwatcharakul, Somrak Choovanichvong, Woraphat Ratta-Aph. Clozapine-induced agranulocytosis and leukopenia: Incidence, associated factors, and rate of hematologic adverse-effects monitoring in psychiatric out-patient services in Thailand. Asian journal of psychiatry. vol 41. 2019-08-13. PMID:30856469. |
the present study aimed to investigate the incidence of agranulocytosis and leukopenia and its associated factors in thai schizophrenia patients treated with clozapine and the rate of hematologic adverse events monitored in clinical practice. |
2019-08-13 |
2023-08-13 |
Not clear |
| René S Kahn, Inge Winter van Rossum, Stefan Leucht, Philip McGuire, Shon W Lewis, Marion Leboyer, Celso Arango, Paola Dazzan, Richard Drake, Stephan Heres, Covadonga M Díaz-Caneja, Dan Rujescu, Mark Weiser, Silvana Galderisi, Birte Glenthøj, Marinus J C Eijkemans, W Wolfgang Fleischhacker, Shitij Kapur, Iris E Somme. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The lancet. Psychiatry. vol 5. issue 10. 2019-08-09. PMID:30115598. |
amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (optimise): a three-phase switching study. |
2019-08-09 |
2023-08-13 |
Not clear |
| René S Kahn, Inge Winter van Rossum, Stefan Leucht, Philip McGuire, Shon W Lewis, Marion Leboyer, Celso Arango, Paola Dazzan, Richard Drake, Stephan Heres, Covadonga M Díaz-Caneja, Dan Rujescu, Mark Weiser, Silvana Galderisi, Birte Glenthøj, Marinus J C Eijkemans, W Wolfgang Fleischhacker, Shitij Kapur, Iris E Somme. Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. The lancet. Psychiatry. vol 5. issue 10. 2019-08-09. PMID:30115598. |
whether switching antipsychotics or early use of clozapine improves outcome in (first-episode) schizophrenia is unknown. |
2019-08-09 |
2023-08-13 |
Not clear |
| Suraj Pathak, Scott Cherry, Samreen Samad, Ambreen Afta. Successful clozapine rechallenge in a patient with suspected drug induced lupus. BMJ case reports. vol 12. issue 4. 2019-08-05. PMID:30948402. |
clozapine is the most effective treatment for patients with refractory schizophrenia. |
2019-08-05 |
2023-08-13 |
Not clear |
| François R Girardin, Antoine Poncet, Arnaud Perrier, Nathalie Vernaz, Mark Pletscher, Caroline F Samer, Jeffrey A Lieberman, Jean Villar. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. The pharmacogenomics journal. vol 19. issue 2. 2019-08-02. PMID:29298994. |
less than 1% of adult patients with schizophrenia taking clozapine develop agranulocytosis, and most of these cases occur within the first weeks of treatment. |
2019-08-02 |
2023-08-13 |
human |
| François R Girardin, Antoine Poncet, Arnaud Perrier, Nathalie Vernaz, Mark Pletscher, Caroline F Samer, Jeffrey A Lieberman, Jean Villar. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. The pharmacogenomics journal. vol 19. issue 2. 2019-08-02. PMID:29298994. |
the current study aimed to evaluate the cost-effectiveness, from a healthcare provider's perspective, of an hla genotype-guided approach in patients with treatment-resistant schizophrenia who were taking clozapine and to compare the results with the current absolute neutrophil count monitoring (ancm) schemes used in the usa. |
2019-08-02 |
2023-08-13 |
human |
| Carolyn Beth McNabb, Rob Kydd, Frederick Sundram, Ian Soosay, Bruce Roy Russel. Differences in white matter connectivity between treatment-resistant and treatment-responsive subtypes of schizophrenia. Psychiatry research. Neuroimaging. vol 282. 2019-07-25. PMID:30412902. |
these data reveal differences in diffusion measures between flr and those eligible for clozapine and suggest that lower fa and greater rd in the corpus callosum could exist as a biomarker of treatment resistance in people with schizophrenia. |
2019-07-25 |
2023-08-13 |
human |
| Ismael Olmos, Manuel Ibarra, Marta Vázquez, Cecilia Maldonado, Pietro Fagiolino, Gustavo Giachett. Population Pharmacokinetics of Clozapine and Norclozapine and Switchability Assessment between Brands in Uruguayan Patients with Schizophrenia. BioMed research international. vol 2019. 2019-07-22. PMID:30956977. |
population pharmacokinetics of clozapine and norclozapine and switchability assessment between brands in uruguayan patients with schizophrenia. |
2019-07-22 |
2023-08-13 |
Not clear |